Publications by authors named "Mark R Middleton"

100Publications

Intratumoural immunotherapies for unresectable and metastatic melanoma: current status and future perspectives.

Br J Cancer 2020 Sep 27;123(6):885-897. Epub 2020 Jul 27.

Department of Dermatology, Venereology and Allergology, University Hospital Schleswig-Holstein, Kiel, Germany.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41416-020-0994-4DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7492252PMC
September 2020

Indirect treatment comparison of nivolumab versus placebo for the adjuvant treatment of melanoma.

Eur J Cancer 2020 Jun 4;132:176-186. Epub 2020 May 4.

University Hospital Essen and German Cancer Consortium, Heidelberg, Germany.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ejca.2020.03.011DOI Listing
June 2020

Peripheral CD8 T cell characteristics associated with durable responses to immune checkpoint blockade in patients with metastatic melanoma.

Nat Med 2020 02 10;26(2):193-199. Epub 2020 Feb 10.

Department of Oncology, University of Oxford & Oxford Cancer Centre, Churchill Hospital, Oxford University Hospitals NHS Foundation Trust, Oxford, UK.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41591-019-0734-6DOI Listing
February 2020

Immunotherapy-related hepatitis: real-world experience from a tertiary centre.

Frontline Gastroenterol 2019 Oct 22;10(4):364-371. Epub 2019 Mar 22.

Hepatology, Translational Gastroenterology Unit and NIHR Oxford Biomedical Research Centre, Oxford, UK.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1136/flgastro-2018-101146DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6788136PMC
October 2019

Correction to: Will the reformed Cancer Drugs Fund address the most common types of uncertainty? An analysis of NICE cancer drug appraisals.

BMC Health Serv Res 2019 03 28;19(1):198. Epub 2019 Mar 28.

Oxford-UCL Centre for the Advancement of Sustainable Medical Innovation, Radcliffe Department of Medicine, University of Oxford, Room 4403, Level 4, John Radcliffe Hospital, Headley Way, Headington, Oxford, OX3 9DU, UK.

View Article

Download full-text PDF

Source
https://bmchealthservres.biomedcentral.com/articles/10.1186/
Publisher Site
http://dx.doi.org/10.1186/s12913-019-4039-8DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6437939PMC
March 2019

Focused Ultrasound Hyperthermia for Targeted Drug Release from Thermosensitive Liposomes: Results from a Phase I Trial.

Radiology 2019 04 15;291(1):232-238. Epub 2019 Jan 15.

From the Institute of Biomedical Engineering, University of Oxford, Old Road Campus Research Building, Oxford OX3 7DQ, England (M.D.G., P.C.L., C.M., R.C., C.C.C.); Nuffield Department of Surgical Sciences, John Radcliffe Hospital, Oxford University Hospitals NHS Foundation Trust, Oxford, England (P.C.L., F.W.); Departments of Radiology (P.C.L., D.Y.F.C., M.A., F.V.G.) and Oncology (M.R.M.), Churchill Hospital, Oxford University Hospitals NHS Foundation Trust, Oxford, England; Department of Oncology, CRUK/MRC Oxford Institute for Radiation Oncology, University of Oxford, Oxford, England (L.K.F., M.S., L.C.); Nuffield Department of Anaesthetics, Oxford University Hospitals Foundation NHS Trust, Oxford, England (S.S.); and Centre for Pathology, Faculty of Medicine, Imperial College London, London, England (R.G.).

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1148/radiol.2018181445DOI Listing
April 2019

VCAM-1-targeted MRI Enables Detection of Brain Micrometastases from Different Primary Tumors.

Clin Cancer Res 2019 01 2;25(2):533-543. Epub 2018 Nov 2.

Department of Oncology, Cancer Research UK and Medical Research Council, Oxford Institute for Radiation Oncology, University of Oxford, Oxford, United Kingdom.

View Article

Download full-text PDF

Source
http://clincancerres.aacrjournals.org/lookup/doi/10.1158/107
Publisher Site
http://dx.doi.org/10.1158/1078-0432.CCR-18-1889DOI Listing
January 2019

Long-term survival with anti-PD-1-based immunotherapy, but what is the best approach?

Authors:
Mark R Middleton

Lancet Oncol 2018 11 22;19(11):1424-1426. Epub 2018 Oct 22.

Department of Oncology, University of Oxford, Old Road Campus, Oxford, OX3 9DU, UK. Electronic address:

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S14702045183075
Publisher Site
http://dx.doi.org/10.1016/S1470-2045(18)30753-8DOI Listing
November 2018

25-hydroxyvitamin D serum levels in patients with high risk resected melanoma treated in an adjuvant bevacizumab trial.

Br J Cancer 2018 10 23;119(7):793-800. Epub 2018 Jul 23.

Cambridge Cancer Centre, Cambridge University Hospitals NHS Foundation Trust, CB2 0QQ, Cambridge, United Kingdom.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41416-018-0179-6DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6189120PMC
October 2018

Will the reformed Cancer Drugs Fund address the most common types of uncertainty? An analysis of NICE cancer drug appraisals.

BMC Health Serv Res 2018 05 31;18(1):393. Epub 2018 May 31.

Oxford-UCL Centre for the Advancement of Sustainable Medical Innovation, Radcliffe Department of Medicine, University of Oxford, Room 4403, Level 4, John Radcliffe Hospital, Headley Way, Headington, Oxford, OX3 9DU, UK.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s12913-018-3162-2DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5984433PMC
May 2018

Phosphatidylinositol 3-Kinase α-Selective Inhibition With Alpelisib (BYL719) in PIK3CA-Altered Solid Tumors: Results From the First-in-Human Study.

J Clin Oncol 2018 05 5;36(13):1291-1299. Epub 2018 Feb 5.

Dejan Juric, Massachusetts General Hospital Cancer Center, Boston; Alan Huang, Novartis Institutes for BioMedical Research, Cambridge, MA; Jordi Rodon and Josep Tabernero, Vall d'Hebron University Hospital and Institute of Oncology, Universitat Autònoma de Barcelona; Marta Gil-Martin, Catalan Institute of Oncology - Bellvitge Biomedical Research Institute (IDIBELL), Barcelona, Spain; Filip Janku, The University of Texas MD Anderson Cancer Center, Houston, TX; Howard A. Burris, Sarah Cannon Research Institute and Tennessee Oncology; Jordan Berlin, Vanderbilt-Ingram Cancer Center, Nashville, TN; Jan H.M. Schellens, Netherlands Cancer Institute, Amsterdam, the Netherlands; Mark R. Middleton, National Institute for Health Research, Oxford Biomedical Research Centre, Churchill Hospital, Oxford, United Kingdom; Martin Schuler, West German Cancer Center, University Duisburg-Essen, and German Cancer Consortium, Partner Site University Hospital Essen, Essen; Ruth Seggewiss-Bernhardt, Comprehensive Cancer Center Mainfranken, University Hospital Würzburg, Würzburg, Germany; Hope S. Rugo, University of California San Francisco Helen Diller Family Comprehensive Cancer Center, San Francisco, CA; Douglas Bootle, David Demanse, Lars Blumenstein, and Cornelia Quadt, Novartis Pharma AG, Basel, Switzerland; Christina Coughlin, Novartis Pharmaceuticals Corporation, East Hanover, NJ; and José Baselga, Memorial Sloan Kettering Cancer Center, New York, NY.

View Article

Download full-text PDF

Source
http://ascopubs.org/doi/10.1200/JCO.2017.72.7107
Publisher Site
http://dx.doi.org/10.1200/JCO.2017.72.7107DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5920739PMC
May 2018

Societal preferences for adjuvant melanoma health states: UK and Australia.

BMC Cancer 2017 Oct 17;17(1):689. Epub 2017 Oct 17.

Outcomes Research Strategies in Health, Washington, DC, 20008, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s12885-017-3673-yDOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5646133PMC
October 2017

Patient-reported outcomes in KEYNOTE-006, a randomised study of pembrolizumab versus ipilimumab in patients with advanced melanoma.

Eur J Cancer 2017 11 4;86:115-124. Epub 2017 Oct 4.

Olivia Newton-John Cancer Research Institute, Austin Health, School of Cancer Medicine, La Trobe University, 145 Studley Road, Heidelberg VIC 3084, Melbourne, Australia. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ejca.2017.08.032DOI Listing
November 2017

Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV Melanoma.

N Engl J Med 2017 11 10;377(19):1824-1835. Epub 2017 Sep 10.

From New York University Perlmutter Cancer Center, New York (J.W.); Papa Giovanni XXIII Cancer Center Hospital, Bergamo (M. Mandala), Medical Oncology, National Cancer Institute, Milan (M.D.V.), Oncology Institute of Veneto Istituti di Ricovero e Cura a Carattere Scientifico, Padua (V.C.-S.), Center for Immuno-Oncology, University Hospital of Siena, Istituto Toscano Tumori, Siena (M. Maio), Ospedale Policlinico San Martino, Genoa (P.Q.), and Istituto Nazionale Tumori Fondazione Pascale, Naples (P.A.A.) - all in Italy; National and Kapodistrian University of Athens, Athens (H.J.G.); Hospital Clinic de Barcelona, Barcelona (A.M.A.), and General University Hospital Gregorio Marañón, Madrid (I.M.-R.) - both in Spain; Texas Oncology-Baylor Cancer Center, Dallas (C.L.C.); Hospices Civils de Lyon, Pierre Bénite (S.D.), Aix-Marseille University, Hospital de la Timone, Marseille (J.-J.G.), Institut Universitaire du Cancer de Toulouse and Centre Hospitalier Universitaire (CHU), Toulouse (N.M.), Université Lille, INSERM Unité 1189, CHU Lille, Lille (L.M.), and Assistance Publique-Hôpitaux de Paris, Dermatology and Centres d'Investigation Clinique, INSERM Unité 976, Hôpital Saint Louis, Université Paris Diderot, Paris (C.L.) - all in France; Oncology Center Sf. Nectarie, Craiova, Romania (M. Schenker); Princess Margaret Cancer Centre, University of Toronto, Toronto (M.O.B.), and Cross Cancer Institute, Edmonton, AB (M. Smylie) - both in Canada; the Department of Oncology, University of Oxford, Oxford (M.R.M.), and Royal Marsden NHS Foundation Trust, London (J.L.) - both in the United Kingdom; Gallipoli Medical Research Foundation and University of Queensland, Queensland, VIC (V.A.), and Melanoma Institute Australia, University of Sydney, and Royal North Shore and Mater Hospitals, Sydney (G.V.L.) - all in Australia; University of Colorado, Denver (R.G.); Winship Cancer Institute, Emory University School of Medicine, Atlanta (R.R.K.); Georgetown-Lombardi Comprehensive Cancer Center, Washington DC (M.B.A.); University of Washington, Seattle (S.B.); Maria Sklodowska-Curie Institute-Oncology Center, Warsaw, Poland (P.R.); Nagoya University Graduate School of Medicine, Nagoya (K.Y.), and the National Cancer Center Hospital, Tokyo (N.Y.) - both in Japan; Seoul National University Hospital, Seoul, South Korea (T.M.K.); and Bristol-Myers Squibb, Princeton, NJ (V.P, J.S., A.Q.).

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1056/NEJMoa1709030DOI Listing
November 2017

Erratum to: Ongoing Response in BRAF V600E-Mutant Melanoma After Cessation of Intermittent Vemurafenib Therapy: A Case Report.

Target Oncol 2017 06;12(3):385

Department of Oncology, NIHR Biomedical Research Centre, Oxford Cancer and Haematology Centre, Churchill Hospital, Old Road, Headington, Oxford, OX3 7LE, UK.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s11523-017-0483-8DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6828243PMC
June 2017

RADVAN: a randomised phase 2 trial of WBRT plus vandetanib for melanoma brain metastases - results and lessons learnt.

Br J Cancer 2016 Nov 6;115(10):1193-1200. Epub 2016 Oct 6.

Department of Oncology, Oxford University Hospitals NHS Foundation Trust, Cancer and Haematology Centre, Churchill Hospital, Old Road, Oxford OX3 7LE, UK.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/bjc.2016.318DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5104891PMC
November 2016

Genetic susceptibility to Barrett's oesophagus: Lessons from early studies.

United European Gastroenterol J 2016 Aug 13;4(4):485-92. Epub 2015 Oct 13.

Molecular and Population Genetics, Wellcome Trust Centre for Human Genetics, University of Oxford, Oxford, UK; NIHR Oxford Biomedical Research Centre, The Joint Research Office, Churchill Hospital, Oxford University Hospitals NHS Foundation Trust, Oxford, UK.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/2050640615611018DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4971784PMC
August 2016

Erratum to: Genetic Biomarkers of Barrett's Esophagus Susceptibility and Progression to Dysplasia and Cancer: A Systematic Review and Meta-Analysis.

Dig Dis Sci 2016 Jul;61(7):2145

Wellcome Trust Centre for Human Genetics, University of Oxford, Roosevelt Drive, Oxford, OX3 7BN, UK.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10620-016-4192-4DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4969759PMC
July 2016

Durable Response of Spinal Chordoma to Combined Inhibition of IGF-1R and EGFR.

Front Oncol 2016 2;6:98. Epub 2016 May 2.

Department of Oncology, Old Road Campus Research Building, Oxford, UK; Oxford Cancer and Haematology Centre, Churchill Hospital, Oxford University Hospitals NHS Foundation Trust, Oxford, UK.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3389/fonc.2016.00098DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4852191PMC
May 2016

Ongoing Response in BRAF V600E-Mutant Melanoma After Cessation of Intermittent Vemurafenib Therapy: A Case Report.

Target Oncol 2016 08;11(4):557-63

Department of Oncology, NIHR Biomedical Research Centre, Oxford Cancer and Haematology Centre, Churchill Hospital, Old Road, Headington, Oxford, OX3 7LE, UK.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s11523-015-0410-9DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5309307PMC
August 2016

Genetic Biomarkers of Barrett's Esophagus Susceptibility and Progression to Dysplasia and Cancer: A Systematic Review and Meta-Analysis.

Dig Dis Sci 2016 Jan 7;61(1):25-38. Epub 2015 Oct 7.

Wellcome Trust Centre for Human Genetics, University of Oxford, Roosevelt Drive, Oxford, OX3 7BN, UK.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10620-015-3884-5DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4700058PMC
January 2016

Ipilimumab in the real world: the UK expanded access programme experience in previously treated advanced melanoma patients.

Melanoma Res 2015 Oct;25(5):432-42

aDepartment of Oncology bCambridge Cancer Trials Centre, Cambridge Clinical Trials Unit - Cancer Theme, Cambridge University Hospitals NHS Foundation Trust, Cambridge cSouthampton Experimental Cancer Medicine Center, University of Southampton and University Hospital Southampton NHS Foundation Trust, Southampton dDepartment of Medical Oncology, The Christie, Manchester eDepartment of Medicine, Royal Marsden NHS Foundation Trust, London fOxford NIHR Biomedical Research Centre, Oxford gDepartment of Medical Oncology, Mount Vernon Hospital, Northwood hDepartment of Medical Oncology, Velindre Cancer Centre, Cardiff iNorthern Centre for Cancer Care, Newcastle upon Tyne jDirectorate of Haematology and Oncology, Guy's and St. Thomas' NHS Foundation Trust, London kDepartment of Medical Oncology, Royal Wolverhampton Hospitals lDepartment of Medical Oncology, Royal Preston Hospital mClinical Oncology, Norfolk and Norwich University Hospital nDivision of Clinical Sciences, St George's Hospital Medical School, London oDepartment of Oncology, Castle Hill Hospital, Hull pSheffield Experimental Cancer Medicine Centre, University of Sheffield, Weston Park Hospital, Sheffield qClinical Oncology Department, Royal Cornwall Hospitals rSt. James's Institute of Oncology, St. James's University Hospital, Leeds, UK.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/CMR.0000000000000185DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4560270PMC
October 2015

Talimogene Laherparepvec Improves Durable Response Rate in Patients With Advanced Melanoma.

J Clin Oncol 2015 Sep 26;33(25):2780-8. Epub 2015 May 26.

Robert H.I. Andtbacka, Huntsman Cancer Institute, University of Utah, Salt Lake City, UT; Howard L. Kaufman, Rutgers Cancer Institute of New Jersey, New Brunswick, NJ; Frances Collichio, University of North Carolina Medical Center, Chapel Hill, NC; Thomas Amatruda, Minnesota Oncology, Fridley, MN; Neil Senzer, Mary Crowley Cancer Research Center, Dallas; Merrick Ross, University of Texas MD Anderson Cancer Center, Houston, TX; Jason Chesney, University of Louisville, Louisville, KY; Keith A. Delman, Winship Cancer Institute, Emory University School of Medicine, Atlanta, GA; Lynn E. Spitler, Northern California Melanoma Center, San Francisco; Gregory A. Daniels, University of California San Diego Medical Center, Moores Cancer Center, La Jolla; Yining Ye, Bin Yao, Ai Li, Ari Vander Walde, and Jennifer Gansert, Amgen, Thousand Oaks, CA; Igor Puzanov, Vanderbilt University, Nashville, TN; Sanjiv S. Agarwala, St Luke's University Hospital and Health Network, Bethlehem, and Temple University School of Medicine, Philadelphia, PA; Mohammed Milhem, University of Iowa Hospitals and Clinics, Iowa City, IA; Lee Cranmer, University of Arizona, Tucson, AZ; Brendan Curti, Earle A. Chiles Research Institute, Portland, OR; Karl Lewis, University of Colorado Cancer Center, Aurora, CO; Troy Guthrie, Baptist Cancer Institute, Jacksonville; Jonathan S. Zager, Moffitt Cancer Center, Tampa, FL; Gerald P. Linette, Washington University School of Medicine, St Louis, MO; Kevin Harrington, Institute of Cancer Research, Royal Marsden Hospital, London; Mark R. Middleton, National Institute for Health Research Biomedical Research Centre, Oxford, United Kingdom; Wilson H. Miller Jr, McGill University, Montreal, Quebec, Canada; and Susan Doleman and Robert S. Coffin, Amgen, Woburn, MA.

View Article

Download full-text PDF

Source
http://www.surgonc.org/docs/default-source/fellows-articles-
Web Search
http://jco.ascopubs.org/content/early/2015/06/16/JCO.2014.58
Web Search
http://jco.ascopubs.org/content/suppl/2015/05/26/JCO.2014.58
Web Search
http://dx.doi.org/10.1200/JCO.2014.58.3377DOI Listing
September 2015

PACMEL: a phase 1 dose escalation trial of trametinib (GSK1120212) in combination with paclitaxel.

Eur J Cancer 2015 Feb 24;51(3):359-66. Epub 2014 Dec 24.

Oxford University Hospitals NHS Trust, Oxford, UK; NIHR Oxford Biomedical Research Centre, Oxford, UK.

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S09598049140114
Publisher Site
http://dx.doi.org/10.1016/j.ejca.2014.11.018DOI Listing
February 2015

Intermittent dosing with vemurafenib in BRAF V600E-mutant melanoma: review of a case series.

Ther Adv Med Oncol 2014 Nov;6(6):262-6

Department of Oncology, NIHR Biomedical Research Centre, Oxford Cancer and Haematology Centre, Churchill Hospital, Old Road, Headington, Oxford, OX3 7LE, UK.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/1758834014548187DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4206651PMC
November 2014

Dsh homolog DVL3 mediates resistance to IGFIR inhibition by regulating IGF-RAS signaling.

Cancer Res 2014 Oct 28;74(20):5866-77. Epub 2014 Aug 28.

Department of Oncology, Weatherall Institute of Molecular Medicine, John Radcliffe Hospital, University of Oxford, Oxford, United Kingdom. Oxford Cancer and Haematology Centre, Oxford University Hospitals NHS Trust, Churchill Hospital, Oxford, Liverpool, United Kingdom.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/0008-5472.CAN-14-0806DOI Listing
October 2014

Individual risk modelling for esophagectomy: a systematic review.

J Gastrointest Surg 2014 Aug 24;18(8):1532-42. Epub 2014 Apr 24.

Oxford Oesophagogastric Centre, Churchill Hospital, Oxford, OX3 7LJ, UK,

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s11605-014-2524-2DOI Listing
August 2014

Optimal duration and timing of adjuvant chemotherapy after definitive surgery for ductal adenocarcinoma of the pancreas: ongoing lessons from the ESPAC-3 study.

J Clin Oncol 2014 Feb 13;32(6):504-12. Epub 2014 Jan 13.

Juan W. Valle, Derek O'Reilly, Manchester Academic Health Sciences Centre, Christie Hospital NHS Foundation Trust and University of Manchester, Manchester; Richard Jackson, Trevor Cox, John P. Neoptolemos, Paula Ghaneh, Charlotte L. Rawcliffe, Liverpool Cancer Research UK Centre and the National Institute for Health Research Pancreas Biomedical Research Unit, University of Liverpool, Liverpool; Daniel Palmer, the Queen Elizabeth Hospital, University Hospital Birmingham NHS Foundation Trust; Deborah D. Stocken, the Cancer Research UK Clinical Trials Unit, University of Birmingham, Birmingham; David Cunningham, Royal Marsden Hospital Foundation Trust, Sutton; Mark R. Middleton, Churchill Hospital, Oxford University Hospitals NHS Trust, Oxford; Alan Anthoney, The Leeds Teaching Hospital Trust, Leeds; Kate Sumpter, Freeman Hospital, Newcastle upon Tyne; Ross Carter, Glasgow Royal Infirmary, Glasgow, United Kingdom; Claudio Bassi, Giovanni Butturini, University of Verona, Verona, Italy; David Goldstein, Bridget A. Robinson, Christos Karapetis, the Australasian Gastro-Intestinal Trials Group, Camperdown, Australia; Andrew Scarfe, University of Alberta, Edmonton, Canada; Francois Lacaine, Hôpital TENON, Assistance Publique Hôpitaux de Paris, Universite Pierre Et Marie Curie, Paris, France; Juhani Sand, Tampere University Hospital, Tampere, Finland; Jakob R. Izbicki, University of Hamburg, Hamburg; Julia Mayerle, Ernst-Moritz-Arndt-Universität Greifswald, Greifswald; Markus W. Büchler, University of Heidelberg, Heidelberg, Germany; Christos Dervenis, the Agia Olga Hospital, Athens, Greece; Attila Oláh, the Petz Aladar Hospital, Gyor, Hungary; Pehr A. Lind, Karolinska-Stockholm Söder Hospital, Stockholm, Sweden.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2013.50.7657DOI Listing
February 2014

Phase II pilot study of intravenous high-dose interferon with or without maintenance treatment in melanoma at high risk of recurrence.

J Clin Oncol 2014 Jan 16;32(3):185-90. Epub 2013 Dec 16.

Miranda J. Payne, Katerina Argyropoulou, Cheng Han, Sandie Wellman, and Mark R. Middleton, National Institute for Health Research Biomedical Research Centre, Oxford University Hospitals National Health Service Trust, Oxford; Paul Lorigan, Christie Hospital, Manchester; James J. McAleer, Cancer Centre, Belfast City Hospital, Belfast, Northern Ireland; David Farrugia, Cheltenham Hospital, Cheltenham; Neville Davidson, Chelmsford Hospital, Chelmsford; Charles Kelly, Newcastle General Hospital, Newcastle upon Tyne; David Chao, Royal Free Hospital, Hampstead; and Ernest Marshall, Clatterbridge Centre for Oncology, Bebington, Wirral, United Kingdom.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2013.49.8717DOI Listing
January 2014

Pancreatic cancer hENT1 expression and survival from gemcitabine in patients from the ESPAC-3 trial.

J Natl Cancer Inst 2014 Jan 3;106(1):djt347. Epub 2013 Dec 3.

Affiliations of authors: Liverpool Cancer Research UK Cancer Trials Unit, Liverpool Cancer Research UK Centre, University of Liverpool, Liverpool, UK (WG, JPN, EG, TFC, PG, EC, CMH, CLR, FC, RJ); the Princess Margaret Hospital, Toronto, Canada (MJM); Manchester Academic Health Sciences Centre, Christie NHS Foundation Trust, School of Cancer and Enabling Sciences, University of Manchester, UK (JWV); Queen Elizabeth Hospital, University Hospital Birmingham NHS Foundation Trust, Birmingham, UK (DHP); Beatson West of Scotland Cancer Centre, Glasgow, UK (ACM); Glasgow Royal Infirmary, Glasgow, UK (RC); Hôpital Tenon, Université, Pierre et Marie Curie, Paris, France (FL); Austin Health, Melbourne, Australia (NCT); Prince of Wales Hospital and Clinical School University of New South Wales, New South Wales, Australia (DG); Nepean Cancer Centre and University of Sydney, Sydney, Australia (JS); Agia Olga Hospital, Athens, Greece (CD); Medical Oncology, Clatterbridge Centre for Oncology, Bebington, Merseyside, UK (DS); Department of Oncology, Akademiska Sjukhuset, Uppsala University, Uppsala, Sweden (BG); University Hospital, North Staffordshire, UK (MD); Freeman Hospital, Newcastle upon Tyne, UK (RMC); Service de Chirurgie Digestive et Viscérale, Hôpital Tenon, Paris, France (FL); Cross Cancer Institute and University of Alberta, Alberta, Canada (JRM, AGS); Churchill Hospital, Oxford University Hospitals NHS Trust, Oxford, UK (MRM); St James's University Hospital, Leeds, UK (AA); Department of Medicine A, University Medicine Greifswald, Greifswald, Germany (JM); Petz Aladar Hospital, Gyor, Hungary (AO); Departments of Surgery and Pathology and ARC-NET Research Center, University of Verona, Italy (AS, CB); Department of Surgery, University of Heidelberg, Heidelberg, Germany (MWB).

View Article

Download full-text PDF

Source
https://academic.oup.com/jnci/article-lookup/doi/10.1093/jnc
Publisher Site
http://dx.doi.org/10.1093/jnci/djt347DOI Listing
January 2014

XPF protein levels determine sensitivity of malignant melanoma cells to oxaliplatin chemotherapy: suitability as a biomarker for patient selection.

Int J Cancer 2014 Mar 14;134(6):1495-503. Epub 2013 Nov 14.

Department of Oncology, Oxford NIHR Biomedical Research Centre, Cancer Research UK-Medical Research Council Gray Institute for Radiation Oncology & Biology, University of Oxford, Oxford, Oxfordshire, OX3 7DQ, United Kingdom.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/ijc.28454DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4233955PMC
March 2014

A phase II study of the potent PARP inhibitor, Rucaparib (PF-01367338, AG014699), with temozolomide in patients with metastatic melanoma demonstrating evidence of chemopotentiation.

Cancer Chemother Pharmacol 2013 May 20;71(5):1191-9. Epub 2013 Feb 20.

Institute for Cancer Research, Paul O'Gorman Building, Newcastle University, Framlington Place, Newcastle upon Tyne NE2 4HH, UK.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00280-013-2113-1DOI Listing
May 2013

New treatment approaches in melanoma: current research and clinical prospects.

Ther Adv Med Oncol 2013 Jan;5(1):73-80

Oxford NIHR Biomedical Research Centre, Churchill Hospital, Oxford, UK.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/1758834012463260DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3539276PMC
January 2013

Ipilimumab: a novel immunomodulating therapy causing autoimmune hypophysitis: a case report and review.

Eur J Endocrinol 2012 Jul 10;167(1):1-5. Epub 2012 Apr 10.

Oxford Centre for Diabetes, Endocrinology and Metabolism, University of Oxford, Oxford OX3 7LE, UK.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1530/EJE-12-0167DOI Listing
July 2012

Oxaliplatin as a radiosensitiser for upper and lower gastrointestinal tract malignancies: what have we learned from a decade of translational research?

Crit Rev Oncol Hematol 2012 Sep 5;83(3):353-87. Epub 2012 Feb 5.

Gray Institute of Radiation Oncology and Biology, Oncology Department, Old Road Campus Research Building, Oxford OX3 7DQ, UK.

View Article

Download full-text PDF

Source
http://linkinghub.elsevier.com/retrieve/pii/S104084281100281
Publisher Site
http://dx.doi.org/10.1016/j.critrevonc.2011.12.007DOI Listing
September 2012

New challenges in endpoints for drug development in advanced melanoma.

Clin Cancer Res 2012 Jan 5;18(2):336-41. Epub 2011 Dec 5.

Department of Medicine, Division of Hematology-Oncology, University of California Los Angeles, CA90095, USA.

View Article

Download full-text PDF

Source
http://clincancerres.aacrjournals.org/cgi/doi/10.1158/1078-0
Publisher Site
http://dx.doi.org/10.1158/1078-0432.CCR-11-2323DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3422891PMC
January 2012

Sentinel lymph node biopsy in melanoma: The Oxford ten year clinical experience.

J Plast Reconstr Aesthet Surg 2011 Oct 25;64(10):1284-90. Epub 2011 May 25.

Department of Plastic & Reconstructive Surgery, John Radcliffe Hospital, Headington, University of Oxford, Department of Oncology, Oxford, OX3 7LJ, UK.

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S17486815110022
Publisher Site
http://dx.doi.org/10.1016/j.bjps.2011.05.001DOI Listing
October 2011

Thyrotoxicosis with pegylated interferon alfa-2b.

Arch Dermatol 2010 Nov;146(11):1273-5

Department of Medical Oncology, Churchill Hospital, Oxford, England.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1001/archdermatol.2010.306DOI Listing
November 2010

Tumor O(6)-methylguanine-DNA methyltransferase inactivation by oral lomeguatrib.

Clin Cancer Res 2010 Jan 12;16(2):743-9. Epub 2010 Jan 12.

Cancer Research UK Carcinogenesis Group, University of Manchester, Paterson Institute for Cancer Research, Manchester, United Kingdom.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-09-1389DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2807621PMC
January 2010

The therapeutic potential of O6-alkylguanine DNA alkyltransferase inhibitors.

Expert Opin Investig Drugs 2007 Oct;16(10):1573-84

Cancer Research UK, Medical Oncology Unit, Churchill Hospital, Oxford OX3 7LJ, UK.

View Article

Download full-text PDF

Source
http://www.tandfonline.com/doi/full/10.1517/13543784.16.10.1
Publisher Site
http://dx.doi.org/10.1517/13543784.16.10.1573DOI Listing
October 2007

Exploiting the role of O6-methylguanine-DNA-methyltransferase (MGMT) in cancer therapy.

Curr Opin Pharmacol 2006 Aug 13;6(4):355-63. Epub 2006 Jun 13.

Cancer Research UK, Medical Oncology Unit, Churchill Hospital, Oxford OX3 7LJ, UK.

View Article

Download full-text PDF

Source
http://linkinghub.elsevier.com/retrieve/pii/S147148920600095
Publisher Site
http://dx.doi.org/10.1016/j.coph.2006.03.011DOI Listing
August 2006

The emerging role of DNA repair proteins as predictive, prognostic and therapeutic targets in cancer.

Cancer Treat Rev 2005 Dec 17;31(8):603-17. Epub 2005 Nov 17.

Cancer Research UK, Medical Oncology Unit, University of Oxford, The Churchill, Oxford Radcliffe Hospitals, Oxford OX3 7LJ, United Kingdom.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ctrv.2005.09.006DOI Listing
December 2005

DNA repair pathways in drug resistance in melanoma.

Anticancer Drugs 2004 Jun;15(5):421-6

Cancer Research UK Medical Oncology Unit, Churchill Hospital, Oxford, UK.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/01.cad.0000127665.74096.93DOI Listing
June 2004

Improvement of chemotherapy efficacy by inactivation of a DNA-repair pathway.

Lancet Oncol 2003 Jan;4(1):37-44

Cancer Research UK Medical Oncology Unit, Churchill Hospital, Oxford, UK.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/s1470-2045(03)00959-8DOI Listing
January 2003

Brain metastases in melanoma: a European perspective.

Semin Oncol 2002 Oct;29(5):513-7

Cancer Research UK Medical Oncology Unit, Churchill Hospital, Oxford, UK.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1053/sonc.2002.35246DOI Listing
October 2002